48 recruiting. 48 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Recruiting 48 |
| Phase 2 | 4 | Recruiting 4 |
Follow Mood Disorders: new trials by email Literature Review of Mood Disorders trials Research Report on Mood Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic Depression Pramipexole, Placebo - Bipolar Disorder (BD) | Phase 3 | Recruiting | Daniel Lindqvist | 126 | 2026-10-01 | 2026-10-22 |
| Brexanolone Lifting Outcomes Of Moms LPCN 1154A, Placebo - Depression, Postpartum, Postpartum Depression (PPD) | Phase 3 | Recruiting | Lipocine Inc. | 120 | 2026-09-01 | 2026-09-16 |
| Lumateperone for Late-Life Depression Lumateperone, Placebo - Treatment Resistant Depression (TRD), Late Life Depression (LLD) | Phase 3 | Recruiting | Eric Lenze | 100 | 2026-09-01 | 2026-09-16 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-10-07 |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant | Phase 3 | Recruiting | Janssen Research & Development, LLC | 348 | 2026-07-23 | 2026-09-25 |
| A Study of MI078 for Postpartum Depression MI078 capsule, Placebo of MI078 capsules - Postpartum Depression (PPD) | Phase 3 | Recruiting | Nanjing Minova Pharmaceutical Co., Ltd. | 200 | 2026-07-10 | 2026-07-23 |
| Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression. Dehydroepiandrosterone (DHEA), Placebo - Treatment Resistant Depression (TRD) | Phase 3 | Recruiting | Charite University, Berlin, Germany | 320 | 2026-06-22 | 2026-09-28 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) Placebo, DT120 - Major Depressive Disorder | Phase 3 | Recruiting | Definium Therapeutics US, Inc. | 165 | 2026-05-10 | 2026-10-23 |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression Ketamine, Oculus VR headset - Treatment Resistant Depression | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 31 | 2026-05-03 | 2026-10-23 |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 600 | 2026-04-30 | 2026-10-01 |
| Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder Psilocybin, Structured Integrated Reframing Therapy (SIRT), Selective Serotonin Reuptake Inhibitor (SSRI) - Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD) | Phase 3 | Recruiting | Khyber Medical University Peshawar | 60 | 2026-04-01 | 2026-07-14 |
| REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version - PTSD - Post Traumatic Stress Disorder | Phase 3 | Recruiting | Senseye, Inc. | 1900 | 2026-02-23 | 2026-04-29 |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol Solriamfetol 150 MG, Placebo - Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 508 | 2026-02-23 | 2026-10-13 |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-02-09 | 2026-10-05 |
| Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia AD + SHR + active LT and extended-release melatonin 2mg, AD + SHR + active LT and placebo melatonin, AD + SHR + placebo LT and extended-release melatonin 2mg - Major Depressive Disorder (MDD) With Insomnia | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 184 | 2026-01-28 | 2026-08-12 |
| Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II. Lacosamide, Placebo - Bipolar Affective Disorder | Phase 3 | Recruiting | University of Sao Paulo | 40 | 2026-01-09 | 2026-02-20 |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder Esketamine, Midazolam, Oral Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 258 | 2026-01-08 | 2026-09-25 |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder CYB003, Psychological Support - Major Depressive Disorder (MDD), Depression in Adults | Phase 3 | Recruiting | Cybin IRL Limited | 330 | 2025-12-10 | 2026-10-30 |
Showing 20 of 48. Sign in to see all of them.
Depressive Disorder, Major (33) · Depression (16) · Bipolar Disorder (11) · Depressive Disorder, Treatment-Resistant (9) · Stress Disorders, Post-Traumatic (3) · Depression, Postpartum (2) · Depressive Disorder (2) · Schizophrenia (2) · Suicidal Ideation (2) · Wounds and Injuries (2) · Anhedonia (1) · Anxiety Disorders (1) · Autism Spectrum Disorder (1) · Combat Disorders (1)
Mental Disorders (48) · Depressive Disorder (38) · Behavior (17) · Behavioral Symptoms (17) · Bipolar and Related Disorders (11) · Nervous System Diseases (4) · Pathological Conditions, Signs and Symptoms (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Dyssomnias (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Neurobehavioral Manifestations (2) · Neurologic Manifestations (2)
Ketamine (5) · lumateperone (4) · Psilocybin (3) · Sertraline (3) · Bupropion (2) · Escitalopram (2) · Esketamine (2) · Lithium (2) · Quetiapine Fumarate (2) · Selective Serotonin Reuptake Inhibitors (2) · Venlafaxine Hydrochloride (2) · seltorexant (2) · Cannabidiol (1) · Celecoxib (1) · Clozapine (1)
Neurocrine Biosciences (5) · Janssen Research & Development, LLC (4) · Dr. Inge Winter (3) · Intra-Cellular Therapies, Inc. (3) · Eli Lilly and Company (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Axsome Therapeutics, Inc. (1) · Bristol-Myers Squibb (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Charite University, Berlin, Germany (1) · Cybin IRL Limited (1) · Daniel Lindqvist (1) · Definium Therapeutics US, Inc. (1) · Douglas Mental Health University Institute (1)
United States (27) · Canada (11) · Spain (9) · Italy (8) · Poland (8) · Bulgaria (7) · China (7) · Taiwan (7) · United Kingdom (7) · Brazil (6) · Germany (6) · Australia (5) · Greece (5) · Japan (5) · Romania (5)
Intra-Cellular Therapies, Inc. Clinical Trial (3) · Alberto AZ Zangrillo, MD (1) · Christian Otte, MD (1) · Conor Liston, MD, PhD (1) · Cristina CC Colombo, MD (1) · Daniel Lindqvist, PhD, MD (1) · Dr Inayat Shah, PhD* (1) · Dr Omer Malik, PhD (1) · Eric J Lenze, MD (1) · Felix Mazer (1)
2023 (4), 2025 (4), I01RD001520 (1), R01MH118388 (1)